Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies

Approximately 40% of patients with diffuse large B cell lymphoma (DLBCL) do not respond or develop relapsed disease after first-line chemoimmunotherapy. A minority of these patients can be cured with autologous hematopoietic stem cell transplantation (AHCT). Although chimeric antigen receptor (CAR)...

Descripción completa

Detalles Bibliográficos
Autor principal: Sawalha, Yazeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708171/
https://www.ncbi.nlm.nih.gov/pubmed/34945817
http://dx.doi.org/10.3390/jpm11121345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708171/
https://www.ncbi.nlm.nih.gov/pubmed/34945817
http://dx.doi.org/10.3390/jpm11121345

Ejemplares similares